【Can-Fite BioPharma-Product CF102】Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19

31^st October 2018 – Can-Fite BioPharma
Limited issued an announcement, which is summarized as follows:

Can-Fite BioPharma Limited provided an update on
its Phase II clinical trial of drug candidate Namodenoson (CF102) for the
treatment of advanced hepatocellular carcinoma (HCC) in patients with Child
Pugh B whose disease has progressed on sorafenib therapy. Due to patient
survival, top line efficacy results are expected during the first quarter of
2019.

The original website link:

https://ir.canfite.com/press-releases/detail/835/due-to-patient-survival-top-line-results-of-the-namodenoson-phase-ii-advanced-liver-cancer-trial-expected-q119